Cargando…

Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis

BACKGROUND—: Although HIV is associated with increased atherosclerotic cardiovascular disease (CVD) risk, it is unknown whether guidelines can identify HIV-infected adults who may benefit from statins. We compared the 2013 American College of Cardiology/American Heart Association and 2004 Adult Trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Binh An P., Weigel, Bernard, Ma, Yifei, Scherzer, Rebecca, Li, Danny, Hur, Sophia, Kalapus, S.C., Deeks, Steven, Hsue, Priscilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516666/
https://www.ncbi.nlm.nih.gov/pubmed/28674084
http://dx.doi.org/10.1161/CIRCIMAGING.116.005995
_version_ 1783251199780192256
author Phan, Binh An P.
Weigel, Bernard
Ma, Yifei
Scherzer, Rebecca
Li, Danny
Hur, Sophia
Kalapus, S.C.
Deeks, Steven
Hsue, Priscilla
author_facet Phan, Binh An P.
Weigel, Bernard
Ma, Yifei
Scherzer, Rebecca
Li, Danny
Hur, Sophia
Kalapus, S.C.
Deeks, Steven
Hsue, Priscilla
author_sort Phan, Binh An P.
collection PubMed
description BACKGROUND—: Although HIV is associated with increased atherosclerotic cardiovascular disease (CVD) risk, it is unknown whether guidelines can identify HIV-infected adults who may benefit from statins. We compared the 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III recommendations in HIV-infected adults and evaluated associations with carotid artery intima-media thickness and plaque. METHODS AND RESULTS—: Carotid artery intima-media thickness was measured at baseline and 3 years later in 352 HIV-infected adults without clinical atherosclerotic CVD and not on statins. Plaque was defined as IMT >1.5 mm in any segment. At baseline, the median age was 43 (interquartile range, 39–49), 85% were men, 74% were on antiretroviral medication, and 50% had plaque. The American College of Cardiology/American Heart Association guidelines were more likely to recommend statins compared with the Adult Treatment Panel III guidelines, both overall (26% versus 14%; P<0.001), in those with plaque (32% versus 17%; P=0.0002), and in those without plaque (16% versus 7%; P=0.025). In multivariable analysis, older age, higher low-density lipoprotein cholesterol, pack per year of smoking, and history of opportunistic infection were associated with baseline plaque. Baseline IMT (hazard ratio, 1.18 per 10% increment; 95% confidence interval, 1.05–1.33; P=0.005) and plaque (hazard ratio, 2.06; 95% confidence interval, 1.02–4.08; P=0.037) were each associated with all-cause mortality, independent of traditional CVD risk factors. CONCLUSIONS—: Although the American College of Cardiology/American Heart Association guidelines recommended statins to a greater number of HIV-infected adults compared with the Adult Treatment Panel III guidelines, both failed to recommend therapy in the majority of HIV-affected adults with carotid plaque. Baseline carotid atherosclerosis but not atherosclerotic CVD risk scores was an independent predictor of mortality. HIV-specific guidelines that include detection of subclinical atherosclerosis may help to identify HIV-infected adults who are at increased atherosclerotic CVD risk and may be considered for statins.
format Online
Article
Text
id pubmed-5516666
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-55166662017-07-31 Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis Phan, Binh An P. Weigel, Bernard Ma, Yifei Scherzer, Rebecca Li, Danny Hur, Sophia Kalapus, S.C. Deeks, Steven Hsue, Priscilla Circ Cardiovasc Imaging Original Articles BACKGROUND—: Although HIV is associated with increased atherosclerotic cardiovascular disease (CVD) risk, it is unknown whether guidelines can identify HIV-infected adults who may benefit from statins. We compared the 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III recommendations in HIV-infected adults and evaluated associations with carotid artery intima-media thickness and plaque. METHODS AND RESULTS—: Carotid artery intima-media thickness was measured at baseline and 3 years later in 352 HIV-infected adults without clinical atherosclerotic CVD and not on statins. Plaque was defined as IMT >1.5 mm in any segment. At baseline, the median age was 43 (interquartile range, 39–49), 85% were men, 74% were on antiretroviral medication, and 50% had plaque. The American College of Cardiology/American Heart Association guidelines were more likely to recommend statins compared with the Adult Treatment Panel III guidelines, both overall (26% versus 14%; P<0.001), in those with plaque (32% versus 17%; P=0.0002), and in those without plaque (16% versus 7%; P=0.025). In multivariable analysis, older age, higher low-density lipoprotein cholesterol, pack per year of smoking, and history of opportunistic infection were associated with baseline plaque. Baseline IMT (hazard ratio, 1.18 per 10% increment; 95% confidence interval, 1.05–1.33; P=0.005) and plaque (hazard ratio, 2.06; 95% confidence interval, 1.02–4.08; P=0.037) were each associated with all-cause mortality, independent of traditional CVD risk factors. CONCLUSIONS—: Although the American College of Cardiology/American Heart Association guidelines recommended statins to a greater number of HIV-infected adults compared with the Adult Treatment Panel III guidelines, both failed to recommend therapy in the majority of HIV-affected adults with carotid plaque. Baseline carotid atherosclerosis but not atherosclerotic CVD risk scores was an independent predictor of mortality. HIV-specific guidelines that include detection of subclinical atherosclerosis may help to identify HIV-infected adults who are at increased atherosclerotic CVD risk and may be considered for statins. Lippincott Williams & Wilkins 2017-07 2017-07-03 /pmc/articles/PMC5516666/ /pubmed/28674084 http://dx.doi.org/10.1161/CIRCIMAGING.116.005995 Text en © 2017 The Authors. Circulation: Cardiovascular Imaging is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
spellingShingle Original Articles
Phan, Binh An P.
Weigel, Bernard
Ma, Yifei
Scherzer, Rebecca
Li, Danny
Hur, Sophia
Kalapus, S.C.
Deeks, Steven
Hsue, Priscilla
Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis
title Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis
title_full Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis
title_fullStr Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis
title_full_unstemmed Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis
title_short Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis
title_sort utility of 2013 american college of cardiology/american heart association cholesterol guidelines in hiv-infected adults with carotid atherosclerosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516666/
https://www.ncbi.nlm.nih.gov/pubmed/28674084
http://dx.doi.org/10.1161/CIRCIMAGING.116.005995
work_keys_str_mv AT phanbinhanp utilityof2013americancollegeofcardiologyamericanheartassociationcholesterolguidelinesinhivinfectedadultswithcarotidatherosclerosis
AT weigelbernard utilityof2013americancollegeofcardiologyamericanheartassociationcholesterolguidelinesinhivinfectedadultswithcarotidatherosclerosis
AT mayifei utilityof2013americancollegeofcardiologyamericanheartassociationcholesterolguidelinesinhivinfectedadultswithcarotidatherosclerosis
AT scherzerrebecca utilityof2013americancollegeofcardiologyamericanheartassociationcholesterolguidelinesinhivinfectedadultswithcarotidatherosclerosis
AT lidanny utilityof2013americancollegeofcardiologyamericanheartassociationcholesterolguidelinesinhivinfectedadultswithcarotidatherosclerosis
AT hursophia utilityof2013americancollegeofcardiologyamericanheartassociationcholesterolguidelinesinhivinfectedadultswithcarotidatherosclerosis
AT kalapussc utilityof2013americancollegeofcardiologyamericanheartassociationcholesterolguidelinesinhivinfectedadultswithcarotidatherosclerosis
AT deekssteven utilityof2013americancollegeofcardiologyamericanheartassociationcholesterolguidelinesinhivinfectedadultswithcarotidatherosclerosis
AT hsuepriscilla utilityof2013americancollegeofcardiologyamericanheartassociationcholesterolguidelinesinhivinfectedadultswithcarotidatherosclerosis